Letter to the Editor
- 30 November 2004
- Vol. 35 (5) , 1222-1224
- https://doi.org/10.1016/j.bone.2004.08.013
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapyBone, 2004
- Subgroup analyses in randomized trials: risks of subgroup-specific analyses;: power and sample size for the interaction testPublished by Elsevier ,2004
- Risedronate Prevents New Vertebral Fractures in Postmenopausal Women at High RiskJournal of Clinical Endocrinology & Metabolism, 2003
- The Impact of Bone Turnover and Bone-Active Agents on Bone Quality: Focus on the HipOsteoporosis International, 2002
- Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive AgentsJournal of Clinical Endocrinology & Metabolism, 2002
- Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention TrialJournal of the American Geriatrics Society, 2002
- Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention TrialJournal of Clinical Endocrinology & Metabolism, 2000
- Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT StudyOsteoporosis International, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Design of the Fracture Intervention TrialOsteoporosis International, 1993